Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
| Autor: | Judith C. Kando, Sheila A. Volpicelli, James G. Flood, Frances R. Frankenburg, Franca Centorrino, Ross J. Baldessarini |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Affective Disorders Psychotic Serotonin reuptake inhibitor Pharmacology Pharmacokinetics Fluoxetine Sertraline Ambulatory Care medicine Humans Drug Interactions Clozapine Aged Middle Aged Paroxetine Stimulation Chemical Psychiatry and Mental health 1-Naphthylamine Anesthesia Schizophrenia Drug Therapy Combination Serotonin Psychology Reuptake inhibitor Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | American Journal of Psychiatry. 153:820-822 |
| ISSN: | 1535-7228 0002-953X |
| DOI: | 10.1176/ajp.153.6.820 |
| Popis: | Objective: The selective serotonin reuptake inhibitor (SSRI) fluoxetine can increase serum levels ofclozapine and norclozapine, but effects ofother SSRIs are unknown. Thus, the authors evaluated interactions ofclozapine with fluoxetine, paroxetine, and sertraline. Method: Serum clozapine and norclozapine concentrations were assayed in 80 psychiatric patients, matched f or age and clozapine dose, given clozapine (mean dose=2 79 mg/day) alone or with fluoxetine (mean dose=39.3 mg/day), paroxetine (mean=31.2 mg/day), or sertraline (mean=92.5 mgi day). Each patient’s dose ofclozapine was stable for at least a month before serum sampling. Results: Concentrations of clozapine plus norclozapine averaged 43 % higher, and the risk of levels higher than 1000 ng/ml was 1 0-fold greater (25%), in the patients taking SSRIs, with minor differences between patients taking the individual SSRIs. Conclusions: SSRIs can increase circulating concentrations ofclozapine and norclozapine, sometimes to potentially toxic levels. (AmJ Psychiatry 1996; 153:820-822) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|